The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $650,000 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Function Therapeutics Inc., a for-profit biotechnology company. The award supports the development of a novel class of small molecule compounds called Parmodulins that can modulate protease-activated receptor 1 (PAR1) signaling to inhibit thromboinflammation. The key objectives are to 1) optimize lead Parmodulin compounds to meet a target product profile suitable for treating hospitalized patients at risk of acute kidney injury (AKI), and 2) validate the efficacy of Parmodulins in a mouse model of ischemic AKI. This project aims to advance a unique therapeutic approach towards clinical stages for preventing and treating AKI, a serious medical condition that frequently affects high-risk patients such as those undergoing major surgery or hospitalized with COVID-19.
Generated 2/25/25, 3:41 AM